# A Phase I Study of SIM0609 in Adult Participants With Locally Advanced/Metastatic Solid Tumors

> **NCT07265921** · PHASE1 · RECRUITING · sponsor: **Jiangsu Simcere Pharmaceutical Co., Ltd.** · enrollment: 232 (estimated)

## Conditions studied

- Advanced Solid Cancer

## Interventions

- **DRUG:** SIM0609 for injection
- **DRUG:** dose expansion of SIM0609 in CRC
- **DRUG:** dose expansion of SIM0609 in GC/GEJC cohort
- **DRUG:** dose expansion of SIM0609 in PDAC cohort
- **DRUG:** dose expansion of SIM0609 in positive other solid tumors

## Key facts

- **NCT ID:** NCT07265921
- **Lead sponsor:** Jiangsu Simcere Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-07
- **Primary completion:** 2028-12
- **Final completion:** 2029-06
- **Target enrollment:** 232 (ESTIMATED)
- **Last updated:** 2025-12-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07265921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07265921, "A Phase I Study of SIM0609 in Adult Participants With Locally Advanced/Metastatic Solid Tumors". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT07265921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*